By Ed Silverman
In September 2009, the Eli Lilly & Co. executive team trumpeted a carefully crafted reorganization of their research and...
Lilly Tries to Buy Time
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?